Individuals Discontinuing Slimming Jabs Regain Weight Far More Rapidly Compared to Those on Conventional Diets

A recent study suggests that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional lifestyle plans.

Published data in a leading medical journal demonstrates that while overweight people frequently drop about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.

"Individuals buying such drugs must be aware of the risk of rapid weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.

This pace of recovery suggests a return to starting mass within about one and a half years.

Weighing Approaches

The analysis, which reviewed 37 of studies involving thousands of patients, contrasted the effects of these new drugs with older methods.

Researchers note that individuals who shed pounds through lifestyle changes alone generally see a more gradual weight regain—around 0.1 kg a month—post-intervention.

Explaining the Fast Rebound

Nutrition scientists suggest the mode of action of the injections is key to understanding the amplified regain.

The injections mimic a body's own chemical called GLP-1, which controls appetite.

"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this medication means hunger is uncontrolled, making binge eating much more probable."

A Chronic Disease?

The NHS suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

Many experts say that, considering the significant potential of relapse, the treatment should be considered long-term.

This perspective is echoed by drug manufacturers, who note that the findings "emphasize the long-term character of obesity," comparing it to managing conditions like high blood pressure.

User Experiences

Individuals who have stopped the jabs explain a powerful return of appetite.

"It felt as if something that goes on and you're instantly starving," said an individual.

The struggle is exacerbated if individuals have not established sustainable dietary or behavioural modifications during therapy.

Growing Interest

Survey data indicate that a significant number of people in the UK have used these injections in the past year, with demand being substantial.

• Use is more common among women compared to males.
• The middle-aged demographic shows the highest level of interest.
• Many obtain the drugs through private healthcare rather than the NHS.

In conclusion, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent fix and long-term success relies on combined behavioural changes.